COMMUNIQUÉS West-GlobeNewswire

Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
17/04/2018
PETALUMA, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the [...]
Orphazyme announces establishment of US subsidiary in Massachusetts
17/04/2018
Orphazyme A/S Investor news No. 06/2018 Copenhagen, April 17, 2018 – Orphazyme A/S , a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the creation of [...]
Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting
17/04/2018
Triple combination of tilsotolimod (IMO-2125), epacadostat (IDO-1) and anti-PD-1 antibody demonstrate maximal anti-tumor efficacy in pre-clinical models CHICAGO, April 17, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals [...]
Dr. Richard W. Hudspeth Joins Carolina Complete Health Networks’ Board of Directors
17/04/2018
RALEIGH, N.C., April 17, 2018 (GLOBE NEWSWIRE) -- Carolina Complete Health Network, Inc. (CCHN), a company formed to build and support a patient-focused, physician-led Medicaid health network, welcomes Richard W. [...]
Clinical Laserthermia Systems and Toronto General Hospital Begin Clinical Study for MRI-Guided Laser Ablation Treatment of Prostate Cancer
17/04/2018
FRAMINGHAM, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc . (CLS Americas) a subsidiary of CLS AB in Lund, Sweden, today announced the commencement of a clinical study with [...]
CellAegis Strengthens Management Team to Support Future Growth
17/04/2018
TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. (“CellAegis” or the “Company”), a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for [...]
BeyondSpring Presents Lead Asset’s Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia
17/04/2018
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced the [...]
MPX Signs a Letter of Intent to Acquire Canadian Licenced Producer Canveda
17/04/2018
TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (“ MPX ” or the “ Company ”) (CSE:MPX) (OTC:MPXEF) is pleased to announce that it has signed a letter of intent (the “ LOI ”) to acquire 100% of [...]
Emerald Health Therapeutics to Launch Award-Winning Endocannabinoid Based Products into Canadian Grocery, Natural Health Product, and Pharmacy Stores
17/04/2018
New joint venture, Emerald Health Naturals, secures exclusive Canadian rights to sell proprietary non-cannabis health products that support the human endocannabinoid system Initiative leverages natural health product [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018
17/04/2018
Company Announcement Net sales of DARZALEX in the first quarter of 2018 totaled USD 432 million Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April 17, 2018 – Genmab A/ [...]
Renaissance BioScience Corp. partners with Mitacs for $1.44-million project to advance its next-generation yeast development platform, tools and methods
17/04/2018
VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- Renaissance BioScience Corp. (RBSC), a leading global yeast technology company, is pleased to announce a new partnership with Mitacs for a multi-year, $1. [...]
Emerald Health Therapeutics Expands Strategic Investment in VANC
17/04/2018
VANC executes supply and distribution agreement with Emerald VANC issues warrants to Emerald VANCOUVER, British Columbia, April 17, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. ( “VANC” ) announced today that it [...]
LIDDS: Kallelse till årsstämma i LIDDS AB (publ)
17/04/2018
Aktieägarna i LIDDS AB (publ), org.nr. 556580-2856, kallas till årsstämma på Virdings allé 32B i Uppsala onsdagen den 16 maj 2018 kl. 15:00. Rätt att delta och anmälan Rätt att delta i bolagsstämman har den aktieägare [...]
Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business
17/04/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business Advent to invest in Zentiva to create a new, [...]
Advent International entre en négociations exclusives pour acquérir Zentiva, l'activité Génériques de Sanofi en Europe
17/04/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Advent International entre en négociations exclusives pour acquérir Zentiva, l'activité Génériques de Sanofi en Europe Advent va investir dans Zentiva [...]
CellaVision AB: The Nomination Committee of CellaVision AB supplements its proposal with an additional Board member
17/04/2018
The information was submitted to the public on April 17, 2018 at 8:20 CET The Nomination Committee presented its proposal to the Annual General Meeting on 4 May 2018 on April 4, 2018. The proposal and the motivated [...]
Posting of UK Annual Report and Accounts & Notice of AGM
17/04/2018
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its 2017 UK Annual [...]
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
17/04/2018
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and implementing capacity- [...]
Novartis renouvelle son engagement afin d'éliminer le paludisme en investissant 100 millions de dollars dans la recherche et le développement d'antipaludiques de nouvelle génération
17/04/2018
L'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'engagement inclut également l' [...]

Pages